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Editorial
Endothelins
a b
¨Thomas F. Luscher , Amir Lerman
a
¨University Hospital, Zurich, Switzerland
bMayo Clinic, Rochester, USA
It is timely indeed to produce a focused issue on endothelin receptor antagonists has markedly stimulated
endothelins ten years after the discovery of this new family this area of research as it allowed to delineate the
of peptides. Although already in the mid-1980’s the group functional importance of these peptides in the cardiovascu-
of Robert Highsmith in Cincinnati observed that cultured lar system both as regulators of vascular tone and structure.
endothelial cells paradoxically contracted isolated blood In addition, endothelin receptor antagonist are a new class
vessels they only suspected that a peptide produced by of cardiovascular drugs at the clinical horizon which may
endothelial cells was involved. In 1988 Yanigasawa and be used in the future to treat patients with hypertension,
Masaki demonstrated that indeed a 21-amino-peptide, coronary artery disease and/or heart failure.
which they called endothelin-1 was produced by endotheli- In this timely focused issue on endothelins, Tomoh
al cells in culture. Furthermore, they were able to show Masaki [1], the discoverer of endothelin, reviews the
that various cardiovascular mediators, in particular con- history of this important basic observation. In addition,
strictors such as angiotensin II and vasopressin, growth Michael Kirchengast reviews the role of endothelin in
factors such as transforming growth factor b-1 and coagu- restenosis, Ton Rabelink [2] the potential of endothelin
lation factors such as thrombin stimulated the de novo receptor antagonists in renal protection and Pierre Moreau
synthesis of the protein. Because of its remarkable potency [3] their possible role to treat arterial hypertension. Fur-
and long lasting action as a vasoconstrictor, endothelin thermore, the focused issue presents 18 original research
attracted a lot of interest in physiology and cardiovascular papers devoted to several aspects of endothelin-mediated
disease. The demonstration that endothelin also could act responses in the cardiovascular system and the effects of
as a mitogen further suggested that it may act as an specific endothelin receptor antagonists. The great variety
important regulator of the circulation in health and in of topics covered reflects the broad interest in these new
particular in disease. Measurements of plasma endothelin peptides and the receptor antagonists in cardiovascular
levels demonstrated that in cardiac shock, congestive heart research.
failure, pulmonary hypertension, acute myocardial infarc-
tion and many other conditions, endothelin concentrations
were elevated. The importance of these observations, References
however, was unclear particularly as endothelin is consid-
ered primarily a paracrine regulatory system rather than a [1] Masaki T. The discovery of endothelins. Cardiovasc Res
1998;39(3):530–533.circulating hormone. The cloning and characterization of
[2] Rabelink TJ, Stroes E, Bouter KP, Morrison P. Endothelin blockersET and ET -receptors on vascular smooth muscle and theA B and renal protection: a new strategy to prevent end-organ damage in
endothelium in the vessel wall as well as in other organs of
cardiovascular disease? Cardiovasc Res 1998;39(3):543–549.
the circulation such as the heart and the kidney allowed a [3] Moreau P. Endothelin in hypertension: A role for receptor antago-
better understanding of the action of these peptides and led nists? Cardiovasc Res 1998;39(3):534–542.
to the development of receptor antagonists. The use of
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